Description
The menopausal transition is a complex physiological phase marked by hormonal fluctuations that significantly impact a woman’s physical, emotional, and metabolic health. This webinar will provide a comprehensive overview of the stages of menopause, common symptoms, and their clinical implications. Participants will gain evidence-based insights into the indications, benefits, risks, and individualization of hormone replacement therapy (HRT). The session will also address patient selection, counseling, and monitoring to ensure safe and effective use of HRT. Designed for healthcare professionals, this discussion aims to support informed decision-making and optimize long-term health outcomes for women during the menopausal transition.
Summary Listen
- Menopause affects 50% of the population, with around a billion women currently in the perimenopause or postmenopause stage. A significant portion experience symptoms that can be debilitating, lasting longer than initially believed, impacting quality of life, bone health, heart health, and brain health.
- The average age of menopause in Western societies is 51, with a normal range between 45 and 55. However, early menopause can occur between 40 and 45, and premature menopause before 40. The stages include premenopause, perimenopause (characterized by hormonal fluctuations and irregular periods), menopause (cessation of periods for 12 months), and postmenopause.
- Symptoms vary significantly in severity and duration, ranging from hot flashes and night sweats to mood changes, sleep disturbances, and vaginal dryness. These symptoms can overlap with other conditions, making accurate diagnosis crucial. Diagnosis is primarily clinical, based on symptoms, and blood tests are generally unnecessary for women over 45.
- Management options include lifestyle modifications (diet, exercise, stress reduction), non-pharmaceutical treatments (hypnotherapy, CBT), non-hormonal medications (SSRIs, SNRIs, gabapentin, fezolinetant), and hormone replacement therapy (HRT). HRT, replacing estrogen and progesterone, is the most effective medical treatment for symptoms and quality of life.
- HRT can reduce the risk of fractures and protect against osteoporosis, particularly in women with premature menopause. It can also have positive impacts on cardiovascular health if initiated early in menopause. The preferred estrogen is 17 betaestradiol, and the preferred progestogens are natural progesterone or dydrogesterone, which have fewer androgenic side effects.
- Transdermal HRT (patches, gels) is favored for women with certain risk factors, while oral HRT may be preferred for its impact on lipid profiles and compliance. Vaginal estrogen is effective for urogenital symptoms. Contraindications for HRT are becoming less strict, with individualized assessment allowing more women to access it.
- Body identical HRT (estradiol and micronized progesterone or dydrogesterone) is recommended, while compounded bioidentical hormones are not. There is no arbitrary limit to HRT duration; it should be individualized based on benefits and risks, assessed annually. Coming off HRT should be gradual to minimize rebound symptoms.
- Potential side effects include irregular bleeding, bloating, breast tenderness, and headaches. The long-term risks include cardiovascular events, endometrial cancer, ovarian cancer, and breast cancer. Transdermal HRT has a lower risk of thrombosis than oral HRT. Estrogen-only HRT has little or no change in breast cancer risk, while combined HRT has a small increased risk.
Sample Certificate
About the Speakers
Dr. Vikram Sinai Talaulikar
Hon. Associate Professor, University College London, Associate Specialist, Reproductive Medicine Unit, University College London Hospitals NHS Foundation Trust, England, United Kingdom
Comments
Comments
You must be logged in to leave a comment.